Key Details
Price
$10.53Annual Revenue
$117.70 MAnnual EPS
-$0.66Annual ROE
-34.00%Beta
1.24Events Calendar
Next earnings date:
Mar 07, 2025Recent quarterly earnings:
Nov 07, 2024Recent annual earnings:
Mar 07, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
NEW YORK, NY / ACCESSWIRE / January 6, 2025 / If you suffered a loss on your Joint Stock Company Kaspi.kz (NASDAQ:KSPI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/joint-stock-company-kaspi-kz-lawsuit-submission-form?prid=121074&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Joint Stock Company Kaspi.kz (NASDAQ: KSPI) between January 19, 2024 and September 19, 2024, both dates inclusive (the “Class Period”), of the important February 18, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.
NEW YORK, NY / ACCESSWIRE / January 6, 2025 / If you suffered a loss on your Joint Stock Company Kaspi.kz (NASDAQ:KSPI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/joint-stock-company-kaspi-kz-lawsuit-submission-form?prid=120963&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / January 6, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Joint Stock Company Kaspi.kz ("Kaspi.kz" or the "Company") (NASDAQ:KSPI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / January 6, 2025 / If you suffered a loss on your Joint Stock Company Kaspi.kz (NASDAQ:KSPI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/joint-stock-company-kaspi-kz-lawsuit-submission-form?prid=120819&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK , Jan. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Joint Stock Company Kaspi.kz (NASDAQ: KSPI). Shareholders who purchased shares of KSPI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
HYOGO, Japan & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TOKYO:4552; “JCR”) and Modalis Therapeutics Corporation (TOKYO:4883; “Modalis”) today announced that they have validated the initial proof of concept in a joint research program for the development of a novel gene therapy for a central nervous system (CNS) disease. Due to the success of the partnership thus far, Modalis and JCR have agreed to proceed to the next phase of their research by entering into a new.
NEW YORK, NY / ACCESSWIRE / January 5, 2025 / If you suffered a loss on your Joint Stock Company Kaspi.kz (NASDAQ:KSPI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/joint-stock-company-kaspi-kz-lawsuit-submission-form?prid=120672&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / January 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Joint Stock Company Kaspi.kz ("Kaspi.kz" or the "Company") (NASDAQ:KSPI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / If you suffered a loss on your Joint Stock Company Kaspi.kz (NASDAQ:KSPI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/joint-stock-company-kaspi-kz-lawsuit-submission-form?prid=120564&wire=1 or contact Joseph E. Levi, Esq.
FAQ
- What is the primary business of Joint?
- What is the ticker symbol for Joint?
- Does Joint pay dividends?
- What sector is Joint in?
- What industry is Joint in?
- What country is Joint based in?
- When did Joint go public?
- Is Joint in the S&P 500?
- Is Joint in the NASDAQ 100?
- Is Joint in the Dow Jones?
- When was Joint's last earnings report?
- When does Joint report earnings?
- Should I buy Joint stock now?